Polyclonal Hyper Immunoglobulin: A Proven Treatment and Prophylaxis Platform for Passive Immunization to Address Existing and Emerging Diseases

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2021 May 19

PMID 34010089

Citations 16

Authors

Tharmala Tharmalingam

Xiaobing Han

Ashley Wozniak

Laura Saward

Affiliations

Soon will be listed here.

Abstract

Passive immunization with polyclonal hyper immunoglobulin (HIG) therapy represents a proven strategy by transferring immunoglobulins to patients to confer immediate protection against a range of pathogens including infectious agents and toxins. Distinct from active immunization, the protection is passive and the immunoglobulins will clear from the system; therefore, administration of an effective dose must be maintained for prophylaxis or treatment until a natural adaptive immune response is mounted or the pathogen/agent is cleared. The current review provides an overview of this technology, key considerations to address different pathogens, and suggested improvements. The review will reflect on key learnings from development of HIGs in the response to public health threats due to Zika, influenza, and severe acute respiratory syndrome coronavirus 2.

Citing Articles

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase.

Ramos K, Okba N, Tan J, Bandawane P, Meade P, Loganathan M mBio. 2024; 15(7):e0108524.

PMID: 38899870 PMC: 11253627. DOI: 10.1128/mbio.01085-24.

SIR+ models: accounting for interaction-dependent disease susceptibility in the planning of public health interventions.

Martignoni M, Raulo A, Linkovski O, Kolodny O Sci Rep. 2024; 14(1):12908.

PMID: 38839831 PMC: 11153654. DOI: 10.1038/s41598-024-63008-9.

Comparison of neutralization potency across passive immunotherapy approaches as potential treatments for emerging infectious diseases.

Ranjbaran H, Ehteshaminia Y, Nadernezhad M, Jalali S, Jadidi-Niaragh F, Pagheh A Heliyon. 2024; 10(1):e23478.

PMID: 38226283 PMC: 10788261. DOI: 10.1016/j.heliyon.2023.e23478.

A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection.

Tai W, Yang K, Liu Y, Li R, Feng S, Chai B Nat Commun. 2023; 14(1):8042.

PMID: 38052844 PMC: 10697968. DOI: 10.1038/s41467-023-43798-8.

Equine Polyclonal Antibodies Prevent Acute Chikungunya Virus Infection in Mice.

Barker D, Han X, Wang E, Dagley A, Anderson D, Jha A Viruses. 2023; 15(7).

PMID: 37515166 PMC: 10384969. DOI: 10.3390/v15071479.

References

Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S . Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009; 200(4):516-23. PMC: 7109959. DOI: 10.1086/600381. View

Masel J, McCracken M, Gleeson T, Morrison B, Rutherford G, Imrie A . Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned. PLoS Negl Trop Dis. 2019; 13(1):e0007060. PMC: 6370234. DOI: 10.1371/journal.pntd.0007060. View

Fox J, Huang L, Tahan S, Powell L, Crowe Jr J, Wang D . A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice. PLoS Pathog. 2020; 16(8):e1008743. PMC: 7433899. DOI: 10.1371/journal.ppat.1008743. View

Joao C, Negi V, Kazatchkine M, Bayry J, Kaveri S . Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies. J Immunol. 2018; 200(6):1957-1963. DOI: 10.4049/jimmunol.1701271. View

Srivastava R, Ramakrishna C, Cantin E . Anti-inflammatory activity of intravenous immunoglobulins protects against West Nile virus encephalitis. J Gen Virol. 2015; 96(Pt 6):1347-1357. PMC: 4635485. DOI: 10.1099/vir.0.000079. View

Davey Jr R, Fernandez-Cruz E, Markowitz N, Pett S, Babiker A, Wentworth D . Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2019; 7(11):951-963. PMC: 6868512. DOI: 10.1016/S2213-2600(19)30253-X. View

Vonarburg C, Loetscher M, Spycher M, Kropf A, Illi M, Salmon S . Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates. Respir Res. 2019; 20(1):99. PMC: 6532128. DOI: 10.1186/s12931-019-1057-3. View

Beigel J, Voell J, Kumar P, Raviprakash K, Wu H, Jiao J . Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis. 2018; 18(4):410-418. PMC: 5871563. DOI: 10.1016/S1473-3099(18)30002-1. View

Vanderven H, Wragg K, Ana-Sosa-Batiz F, Kristensen A, Jegaskanda S, Wheatley A . Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection. J Infect Dis. 2018; 218(9):1383-1393. PMC: 6927892. DOI: 10.1093/infdis/jiy328. View

10.

Luke T, Wu H, Zhao J, Channappanavar R, Coleman C, Jiao J . Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med. 2016; 8(326):326ra21. DOI: 10.1126/scitranslmed.aaf1061. View

11.

Martins K, Gregory M, Valdez S, Sprague T, Encinales L, Pacheco N . Neutralizing Antibodies from Convalescent Chikungunya Virus Patients Can Cross-Neutralize Mayaro and Una Viruses. Am J Trop Med Hyg. 2019; 100(6):1541-1544. PMC: 6553899. DOI: 10.4269/ajtmh.18-0756. View

12.

Zhang Z, Xie Y, Hong J, Zhang X, Kwok S, Huang X . Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion. 2005; 45(7):1160-4. PMC: 7201861. DOI: 10.1111/j.1537-2995.2005.00179.x. View

13.

Mlakar J, Korva M, Tul N, Popovic M, Poljsak-Prijatelj M, Mraz J . Zika Virus Associated with Microcephaly. N Engl J Med. 2016; 374(10):951-8. DOI: 10.1056/NEJMoa1600651. View

14.

Jones K, Patel N, Levy M, Storeygard A, Balk D, Gittleman J . Global trends in emerging infectious diseases. Nature. 2008; 451(7181):990-3. PMC: 5960580. DOI: 10.1038/nature06536. View

15.

Eke A, Eleje G, Eke U, Xia Y, Liu J . Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst Rev. 2017; 2:CD008545. PMC: 6464495. DOI: 10.1002/14651858.CD008545.pub2. View

16.

Arnon S, Schechter R, Maslanka S, Jewell N, Hatheway C . Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006; 354(5):462-71. DOI: 10.1056/NEJMoa051926. View

17.

Boyer L, Theodorou A, Berg R, Mallie J, Chavez-Mendez A, Garcia-Ubbelohde W . Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med. 2009; 360(20):2090-8. DOI: 10.1056/NEJMoa0808455. View

18.

Baxter D . Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007; 57(8):552-6. DOI: 10.1093/occmed/kqm110. View

19.

de la Lastra J, Baca-Gonzalez V, Asensio-Calavia P, Gonzalez-Acosta S, Morales-delaNuez A . Can Immunization of Hens Provide Oral-Based Therapeutics against COVID-19?. Vaccines (Basel). 2020; 8(3). PMC: 7565424. DOI: 10.3390/vaccines8030486. View

20.

Wang R, Hozumi Y, Yin C, Wei G . Decoding SARS-CoV-2 Transmission and Evolution and Ramifications for COVID-19 Diagnosis, Vaccine, and Medicine. J Chem Inf Model. 2020; 60(12):5853-5865. PMC: 7318555. DOI: 10.1021/acs.jcim.0c00501. View